UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Berotralstat in hereditary angioedema due to C1 inhibitor deficiency: first real-world evidence from a Canadian center

Frontiers in immunology, 2024, Vol.15, p.1339421-1339421

2024

Volltextzugriff (PDF)

Centralized care model for hereditary angioedema overcomes geographical barriers

Frontiers in immunology, 2024-07, Vol.15, p.1413547

2024

Volltextzugriff (PDF)

Efficacy and safety of givosiran for acute hepatic porphyria: 24‐month interim analysis of the randomized phase 3 ENVISION study

Liver international, 2022-01, Vol.42 (1), p.161-172

2022

Volltextzugriff (PDF)

Antibody Responses in SARS-CoV-2-Exposed and/or Vaccinated Individuals Target Conserved Epitopes from Multiple CoV-2 Antigens

International journal of molecular sciences, 2024-09, Vol.25 (18), p.9814

2024

Volltextzugriff (PDF)

The International/Canadian Hereditary Angioedema Guideline

Allergy, asthma, and clinical immunology, 2019-11, Vol.15 (1), p.72-72, Article 72

2019

Volltextzugriff (PDF)

Investigation of a synonymous mutation in Btk in a patient with agammaglobulinemia: A case report

Immunity, Inflammation and Disease, 2023-10, Vol.11 (10), p.e1049-e1049

2023

Volltextzugriff (PDF)

Successful use of lanadelumab in a patient with hereditary angioedema with normal C1 inhibitor and negative genetic testing

The journal of allergy and clinical immunology. Global, 2023-05, Vol.2 (2), p.100087, Article 100087

2023

Volltextzugriff (PDF)

Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks

Journal of allergy and clinical immunology, 2009-10, Vol.124 (4), p.801-808

2009

Volltextzugriff (PDF)

Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig ® ]) in the treatment of patients with primary immunodeficiencies

Frontiers in immunology, 2022-12, Vol.13, p.1110388-1110388

2022

Volltextzugriff (PDF)

Economic impact of self-administered subcutaneous versus clinic-administered intravenous immunoglobulin G therapy in Alberta, Canada: a population-based cohort study

Allergy, asthma, and clinical immunology, 2022-11, Vol.18 (1), p.99-99, Article 99

2022

Volltextzugriff (PDF)

Late-Onset Lymphopenia and ITP in a Patient with Hyper IgM Syndrome Due to a Homozygous Variant in AICDA

Journal of clinical immunology, 2023-10, Vol.43 (7), p.1540-1542

2023

Volltextzugriff (PDF)

T&T Clark Handbook of Thomas F. Torrance , by Paul D. Molnar and Myk Habets, eds

Journal of reformed theology, 2023-07, Vol.17 (2), p.233-234

Ritchie, Bruce

2023

Volltextzugriff (PDF)

Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies

Frontiers in immunology, 2019-02, Vol.10, p.40

2019

Volltextzugriff (PDF)

A comparative evaluation of poly- l -lysine-palmitic acid and Lipofectamine ™ 2000 for plasmid delivery to bone marrow stromal cells

Biomaterials, 2007-11, Vol.28 (31), p.4693-4704

2007

Volltextzugriff (PDF)

Biomarker risk assessment model identified high-risk patients with cancer who benefit from thromboprophylaxis

Annals of internal medicine, 2024-02, Vol.177 (2), p.JC22

2024

Volltextzugriff (PDF)

Rationale and design of the multi organ inflammation with serial testing study: a comprehensive assessment of functional and structural abnormalities in patients with recovered COVID-19

Frontiers in medicine, 2024-07, Vol.11, p.1392169

2024

Volltextzugriff (PDF)

Population pharmacokinetics of plasma-derived C1 esterase inhibitor concentrate used to treat acute hereditary angioedema attacks

Annals of allergy, asthma, & immunology, 2010-08, Vol.105 (2), p.149-154

2010

Volltextzugriff (PDF)

Correction to: The International/Canadian Hereditary Angioedema Guideline

Allergy, asthma, and clinical immunology, 2020-05, Vol.16 (1), p.33-33, Article 33

2020

Volltextzugriff (PDF)

Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study

Thrombosis and haemostasis, 2018-05, Vol.118 (5), p.842-851

2018

Volltextzugriff (PDF)

Clinical perspectives of emerging pathogens in bleeding disorders

The Lancet (British edition), 2006-01, Vol.367 (9506), p.252-261

2006

Volltextzugriff (PDF)

Subcutaneous immunoglobulin for patients with idiopathic inflammatory myopathies: a real-world, single-centre experience

Rheumatology (Oxford, England), 2024-08, Vol.63 (8), p.2118-2122

2024

Volltextzugriff (PDF)

Protease inhibitors in the treatment of hereditary angioedema

Transfusion and apheresis science, 2003-12, Vol.29 (3), p.259-267

Ritchie, Bruce C.

2003

Volltextzugriff (PDF)

Gut microbiota of healthy Canadian infants: profiles by mode of delivery and infant diet at 4 months

Canadian Medical Association journal (CMAJ), 2013-03, Vol.185 (5), p.385-394

2013

Volltextzugriff (PDF)

Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial

The Lancet (British edition), 2022-03, Vol.399 (10328), p.945-955

2022

Volltextzugriff (PDF)

Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet (British edition), 2023-04, Vol.401 (10382), p.1079-1090

2023

Volltextzugriff (PDF)

1 – 25 von 486

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(443)
Mit Volltextzugriff
(377)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(483)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Berotralstat in hereditary angioedema due to C1 inhibitor deficiency: first real-world evidence from a Canadian center

Centralized care model for hereditary angioedema overcomes geographical barriers

Efficacy and safety of givosiran for acute hepatic porphyria: 24‐month interim analysis of the randomized phase 3 ENVISION study

Antibody Responses in SARS-CoV-2-Exposed and/or Vaccinated Individuals Target Conserved Epitopes from Multiple CoV-2 Antigens

The International/Canadian Hereditary Angioedema Guideline

Investigation of a synonymous mutation in Btk in a patient with agammaglobulinemia: A case report

Successful use of lanadelumab in a patient with hereditary angioedema with normal C1 inhibitor and negative genetic testing

Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks

Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig ® ]) in the treatment of patients with primary immunodeficiencies

Economic impact of self-administered subcutaneous versus clinic-administered intravenous immunoglobulin G therapy in Alberta, Canada: a population-based cohort study

Late-Onset Lymphopenia and ITP in a Patient with Hyper IgM Syndrome Due to a Homozygous Variant in AICDA

T&T Clark Handbook of Thomas F. Torrance , by Paul D. Molnar and Myk Habets, eds

Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies

A comparative evaluation of poly- l -lysine-palmitic acid and Lipofectamine ™ 2000 for plasmid delivery to bone marrow stromal cells

Biomarker risk assessment model identified high-risk patients with cancer who benefit from thromboprophylaxis

Rationale and design of the multi organ inflammation with serial testing study: a comprehensive assessment of functional and structural abnormalities in patients with recovered COVID-19

Population pharmacokinetics of plasma-derived C1 esterase inhibitor concentrate used to treat acute hereditary angioedema attacks

Correction to: The International/Canadian Hereditary Angioedema Guideline

Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study

Clinical perspectives of emerging pathogens in bleeding disorders

Subcutaneous immunoglobulin for patients with idiopathic inflammatory myopathies: a real-world, single-centre experience

Protease inhibitors in the treatment of hereditary angioedema

Gut microbiota of healthy Canadian infants: profiles by mode of delivery and infant diet at 4 months

Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial

Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Suchergebnisse filtern